Prophylactic Hiv Drugs Market

Prophylactic HIV drugs Market: Global Industry Analysis 2014 - 2018 and Opportunity Assessment 2019 - 2029

  • Ongoing
  • June 2020
  • REP-GB-9582
  • PDF PPT EXCEL
Prophylactic Hiv Drugs Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Prophylactic Hiv Drugs market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Prophylactic Hiv Drugs market.


Prophylactic HIV drugs: Market Insights

HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor to the global burden diseases. According to World Health Organization statistics report, an estimate of around 36.9 million people are living with HIV in 2017 and 21.7 million people had received antiretroviral treatment by the end of 2017. Prophylactic HIV is a course of HIV treatment which is prescribed by physicians to prevent HIV infection in certain circumstances. It is an emergency treatment given after possible HIV exposure to prevent HIV infection. Prophylactic HIV drugs such as antiretroviral (ARV) is generally used to prevent HIV infection.

Prophylactic HIV drugs: Market Dynamics

Prophylactic HIV drugs witness to have considerable growth in the market since it reduces the chances of HIV infection. Moreover due to its cost effectiveness, there is a high demand among people for prophylactic HIV drugs. In addition to this, increasing prevalence of HIV infection and its treatment, growing government initiatives in spreading awareness among people about the HIV causes, symptom, precautions and treatment and launch of new novel drugs for the treatment is likely to drive the growth of the prophylactic HIV drugs market. However, stringent government regulation in approval and launch of drugs may restrain the growth of the prophylactic HIV drugs. Apart from this, potential side effects of the prophylactic HIV drugs may hamper the growth of the prophylactic HIV drugs market.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

 Prophylactic HIV drugs Market: Overview

Prophylactic HIV drugs market is likely to trigger increase in growth of the market. Prophylactic HIV drugs mostly consists of three anti-HIV drugs such as a fixed-dose combination tablet combining tenofovir, emtricitabine and raltegravir. Mostly prophylactic HIV drugs are recommended during receptive anal sex, vaginal sex, non-sterile injection equipment etc. and thus there is a high demand for the prophylactic HIV drugs in the market. With the increasing prevalence of HIV infection every year, the prophylactic HIV drugs market will spur the growth of the market. However, there are certain complications in prophylactic HIV drugs market.  Irregular dosing of prophylactic HIV drugs may cause harm to the patients. Moreover potential side effects by prophylactic HIV drugs adds another factor which may impact the growth of the prophylactic HIV drugs market.

Prophylactic HIV drugs: Region-wise Outlook

On the basis of geography, the global prophylactic HIV drugs market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan and Middle East & Africa. North America is projected to hold the substantial share in the prophylactic HIV drugs market due to rising adoption of new therapeutics and advanced healthcare facilities. Europe market witness to spur the growth of the prophylactic HIV drugs market due to increasing prevalence and incidences of HIV infection and rising adoption of new medications. Asia Pacific also shown to have potential in stimulating the growth of the prophylactic HIV drugs market due to increasing government initiatives in spreading awareness among people and high demand for new treatment options. Japan seems to have tremendous potential to grow the overall prophylactic HIV drugs market due to rising HIV infection and innovation in new technologies. Middle East & Africa have relatively less growth in prophylactic HIV drugs market due to lack of poor economy and lack of awareness about diseases may hinder the growth of prophylactic HIV drugs market.

Prophylactic HIV drugs Market: Key Players

Some of the key players present across the value chain of the global prophylactic HIV drugs market are Gilead Sciences, Inc, Merck Sharp & Dohme Corp.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Prophylactic Hiv Drugs Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Prophylactic HIV drugs Market: Segmentation

The global prophylactic HIV drugs market is segmented by drug class and distributional channel

Segmentation by Drug Class

  • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  • Integrase Inhibitor

Segmentation by Distributional Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Prophylactic Hiv Drugs Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Prophylactic Hiv Drugs Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology